As per the statistics of World Health Organization (WHO), Colorectal Cancer (CRC) is the third most prevalent cancer in the world along with fourth leading cause of cancer related deaths. Colon and rectal cancers account for most of the glandular malignancies with the incidences increasing with age. Highly penetrant, autosomal dominantly or recessively inherited tumour predispositions cause about 5% of all colorectal cancers. More than 945 000 people are diagnosed with colorectal cancer each year, with roughly 492 000 patients dying. This type of cancer occurs infrequently, often as a result of genetic cancer syndromes or inflammatory bowel illnesses. As per the GLOBOCAN database documented 1.8 million newly diagnosed cases of CRC and 861,600 cases of CRC-related mortality over the world. CRC is a highly diverse disease caused mostly by interactions between genetic changes and environmental variables. Despite advances in diagnosis and treatment, the survival rate of CRC patients has remained unchanged over the previous two decades, with more than half of patients having regional or distant metastasis at the time of diagnosis. Several genes and cellular signalling pathways, including RACK1 (receptor for activated C kinase 1) and long non- coding RNA breast cancer anti-estrogen resistance 4 (lncRNA BCAR4), have been implicated in the formation and progression of CRC. RACK1 expression, for example, has been shown to be considerably upregulated in CRC tissues when compared to adjacent normal tissues.